skip to content
Systematic Reviews of Treatments for Liver Cancer
Follow the links below to find summaries of systematic reviews of the evidence for the effectiveness of treatments for liver cancer.
Reviewed August 2011
15 Resources Found
Results 1 to 15 displayed.
| Title: | Methods of decreasing infection to improve outcomes after liver resections |
|---|---|
| Publisher: | John Wiley and Sons, Ltd. for The Cochrane Collaboration |
| Description: | Liver resections involve removing a part of the liver mainly for cancer or pre-cancerous growths. Liver resections are major operations associated with about 3.5% risk of death and about 10% to 15% risk of major post-operative complications (defined as ... |
| Date: | Aug 2011 |
| Title: | Resection versus no intervention or other surgical interventions for colorectal cancer liver metastases |
|---|---|
| Publisher: | John Wiley and Sons, Ltd. for The Cochrane Collaboration |
| Description: | Almost half of patients with colorectal cancer develop metastases many of which are located in the liver, and a quarter of which may be amendable to surgery. If all disease is removed these patients have a 30% to 50% chance of survival at five years.Tre... |
| Date: | Jul 2011 |
| Title: | Lack of evidence to support or refute transarterial chemoembolisation or transarterial embolisation for patients with unresectable hepatocellular carcinoma |
|---|---|
| Publisher: | John Wiley and Sons, Ltd. for The Cochrane Collaboration |
| Description: | Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the third most common cause of death from cancer. Several interventions have been tried in order to prolong survival and improve quality of life for such patients. During the l... |
| Date: | Feb 2011 |
| Title: | Hepatic arterial infusion versus systemic chemotherapy for colorectal cancer liver metastasis |
|---|---|
| Publisher: | John Wiley and Sons, Ltd. for The Cochrane Collaboration |
| Description: | The standard treatment for unresectable liver-confined metastatic disease from colorectal cancer (CRC) is systemic chemotherapy (SCT). Unfortunately, the prognosis of these patients is dismal and SCT is virtually never curative. Although locoregional tr... |
| Date: | Jan 2011 |
| Title: | Lamivudine with or without adefovir dipivoxil for postoperative hepatocellular carcinoma |
|---|---|
| Publisher: | John Wiley and Sons, Ltd. for The Cochrane Collaboration |
| Description: | Hepatocellular carcinoma (HCC) is among the most common types of cancer. Surgical resection is considered the first-line therapy in early HCC, relapse is the main postoperative problem. A large proportion of participants with HCC have hepatitis B virus ... |
| Date: | Jul 2010 |
| Title: | No evidence from randomised clinical trials for optimal management of patients with large bowel cancer spread to lymph glands draining the liver |
|---|---|
| Publisher: | John Wiley and Sons, Ltd. for The Cochrane Collaboration |
| Description: | Nearly a third of patients with large bowel cancers (colorectal cancer) spread to the liver (liver metastases) within five years of diagnosis of bowel cancer. The affected part of the liver can be removed surgically in a quarter of such patients who dev... |
| Date: | Sep 2009 |
| Title: | Radioactive beads given in addition to chemotherapy does not improve control of cancer nor survival in patients with colorectal cancer and metastasis in the liver. |
|---|---|
| Publisher: | John Wiley and Sons, Ltd. for The Cochrane Collaboration |
| Description: | Bowel cancer commonly spreads to the liver. In most patients this cannot be removed by an operation and cure is not possible. Chemotherapy treatment can help control the growth of the cancer and improve survival. Radioactive beads can be injected into t... |
| Date: | Jul 2009 |
| Title: | No evidence to evaluate the potential benefits and harms of cryotherapy in the treatment of hepatocellular carcinoma |
|---|---|
| Publisher: | John Wiley and Sons, Ltd. for The Cochrane Collaboration |
| Description: | Liver cell cancer (hepatocellular carcinoma) is the most common primary cancer of the liver. Liver cancer is regarded as the third most common cause of death from cancer. Only a minority of the patients are candidates for liver surgery or liver transpla... |
| Date: | Jun 2009 |
| Title: | Percutanous interventions for early hepatocellular carcinoma |
|---|---|
| Publisher: | John Wiley and Sons, Ltd. for The Cochrane Collaboration |
| Description: | Hepatocellular carcinoma (liver cancer) ranks fifth in global cancer burden. Percutaneous techniques such as percutaneous ethanol injection, percutaneous acetic acid injection, and radiofrequency thermal ablation, cryoablation, and transarterial chemoem... |
| Date: | May 2009 |
| Title: | No evidence for optimal management of patients with unresectable liver spread originating from intestinal hormone cells |
|---|---|
| Publisher: | John Wiley and Sons, Ltd. for The Cochrane Collaboration |
| Description: | Liver metastases (liver spread) from gastrointestinal neuroendocrine tumours (cancer of intestinal hormone cells which originate from the embryonic nerve cells or the embryonic outer coat) are generally treated with surgery if a complete removal is deem... |
| Date: | Jul 2008 |
| Title: | No evidence from randomised clinical trial for optimal management of resectable liver spread originating from intestinal hormone cells |
|---|---|
| Publisher: | John Wiley and Sons, Ltd. for The Cochrane Collaboration |
| Description: | Liver spread from hormone-producing cancer of intestinal hormone cells is generally treated by liver resection surgery (removing the affected parts of the liver) if it is possible to remove all the cancer deposits and is associated with good long-term s... |
| Date: | Jul 2008 |
| Title: | Not enough evidence to show if anti-cancer drugs before and after surgery increase survival in liver cell cancer patients |
|---|---|
| Publisher: | John Wiley and Sons, Ltd. for The Cochrane Collaboration |
| Description: | Hepatocellular carcinoma, the commonest primary cancer of the liver is the sixth most common cancer in the world. According to the World Health Organization, most cases of hepatocellular carcinoma occur in Asia and Africa, however recent reports suggest... |
| Date: | Apr 2007 |
| Title: | Tamoxifen does not improve survival in patients with hepatocellular carcinoma |
|---|---|
| Publisher: | John Wiley and Sons, Ltd. for The Cochrane Collaboration |
| Description: | Hepatocellular carcinoma (primary liver cancer) is a common cause of death from cancer world-wide. It is usually fatal in patients who cannot be treated with surgery or other local treatments. Tamoxifen is an anti-oestrogen drug, which has been tested i... |
| Date: | May 2004 |
| Title: | Still awaiting evidence on the effect of radiofrequency thermal ablation for the treatment of hepatocellular carcinoma |
|---|---|
| Publisher: | John Wiley and Sons, Ltd. for The Cochrane Collaboration |
| Description: | Hepatocellular carcinoma is one of the most common malignancies worldwide. Only a minority of the patients can be treated by surgery. Several minimally invasive treatment techniques have been developed to treat patients with hepatocellular carcinoma. Am... |
| Date: | Feb 2004 |
| Title: | Inadequate evidence on screening with alpha-fetoprotein and/or ultrasound of the liver for patients with chronic hepatitis B |
|---|---|
| Publisher: | John Wiley and Sons, Ltd. for The Cochrane Collaboration |
| Description: | There is inadequate evidence to decide whether screening for liver cancer with alpha-fetoprotein and/or ultrasound of the liver compared to no screening is beneficial to patients infected with the hepatitis B virus. Only two randomised trials could be i... |
| Date: | Nov 2002 |
Results 1 to 15 displayed.
